Dana Boyle Sells 1,600 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) CAO Dana Boyle sold 1,600 shares of Liquidia stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $87.53, for a total transaction of $140,048.00. Following the transaction, the chief accounting officer directly owned 167,919 shares in the company, valued at $14,697,950.07. This represents a 0.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dana Boyle also recently made the following trade(s):

• On Monday, July 13th, Dana Boyle sold 9,002 shares of Liquidia stock. The stock was sold at an average price of $71.51, for a total transaction of $643,733.02.

Liquidia Stock Down 0.0%

Shares of LQDA stock opened at $86.80 on Friday. The company has a market capitalization of $7.72 billion, a price-to-earnings ratio of 620.04 and a beta of 0.55. Liquidia Corporation has a one year low of $16.82 and a one year high of $91.10. The company’s fifty day moving average price is $73.31 and its 200-day moving average price is $51.72. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. The company’s quarterly revenue was up 4187.1% compared to the same quarter last year. Sell-side analysts expect that Liquidia Corporation will post 3.02 EPS for the current fiscal year.

Hedge Funds Weigh In On Liquidia

Several institutional investors have recently added to or reduced their stakes in the company. Handelsbanken Fonder AB bought a new stake in Liquidia in the 2nd quarter worth approximately $1,993,000. Fulcrum Equity Management bought a new position in shares of Liquidia during the 2nd quarter valued at approximately $399,000. Fluent Financial LLC purchased a new position in shares of Liquidia in the second quarter valued at $287,000. FNY Investment Advisers LLC purchased a new position in shares of Liquidia in the second quarter valued at $1,395,000. Finally, Seven Fleet Capital Management LP grew its holdings in shares of Liquidia by 124.5% in the first quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock valued at $7,732,000 after purchasing an additional 113,609 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Wall Street Analyst Weigh In

LQDA has been the subject of a number of recent analyst reports. Needham & Company LLC upped their price objective on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Oppenheimer set a $75.00 price target on Liquidia in a report on Friday, June 5th. Stephens set a $130.00 price objective on shares of Liquidia in a report on Friday, July 24th. Jefferies Financial Group reiterated a “buy” rating and set a $60.00 price objective on shares of Liquidia in a research report on Monday, May 11th. Finally, BTIG Research boosted their target price on shares of Liquidia from $59.00 to $109.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. Three research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $86.18.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).